Fuan Pharmaceutical (Group) Co., Ltd.: history, ownership, mission, how it works & makes money

Founded on February 25, 2004 in Chongqing and listed on the Shenzhen Stock Exchange in March 2011 (ticker 300194.SZ), Fuan Pharmaceutical has grown into a cGMP-compliant, vertically integrated group with nine subsidiaries, about 3,392 employees and headquarters at No. 2 Huangyang Road, Yubei District, Chongqing; the company - with a registered capital of approximately 281.99 million yuan and roughly 1.19 billion shares outstanding - maintains a net cash position (cash and equivalents of 846.3 million yuan versus total debt of 527.4 million yuan) while generating revenue through APIs, intermediates and finished dosage forms across anti-infective, anti-tumor, cardiovascular and digestive therapy areas; in 2024 Fuan reported revenue of 2.39 billion yuan (down 9.68% year-on-year) and net income of 279.84 million yuan (up 20.69%), and in H1 2025 posted net profit attributable to shareholders of 113 million yuan (a 47.74% decrease year-on-year) with a mid-2025 guidance of 100-130 million yuan (forecast decline of 39.95%-53.81%), reflecting both operational resilience and near-term market pressure that readers should explore further in the full article.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): Intro

• Founded: February 25, 2004 (Chongqing, China)
• Listing: March 2011 - Shenzhen Stock Exchange, ticker 300194
• Name change: August 2013 to Fuan Pharmaceutical (Group) Co., Ltd.
• Employees (2025): ~3,392
• Subsidiaries: 9 (see list below)
• Quality: Facilities operate under cGMP compliance

• Key subsidiaries:
  • Chongqing Bosen Pharmaceutical Co., Ltd.
  • Ningbo Tianheng Pharmaceutical Co., Ltd.
  • Hubei Renmin Pharmaceutical Co., Ltd.
  • Plus six additional manufacturing/marketing subsidiaries covering APIs, formulations and distribution

• Product portfolio: prescription pharmaceuticals, bulk active pharmaceutical ingredients (APIs), finished-dosage formulations, and OTC products sold through hospitals, pharmacies and distributors.
• Revenue streams:
  • Sales of APIs and finished formulations to domestic hospitals and distributors.
  • Contract manufacturing and toll-processing for third parties.
  • Licensing and technology transfer agreements for selected products/formulations.
• Manufacturing footprint: multiple production lines across subsidiaries enabling scale in API production and formulation, with cGMP certification supporting both domestic hospital procurement and third-party OEM contracts.
• Commercial channels: institutional hospital procurement (key for chronic and hospital-use drugs), retail pharmacy distribution, and regional distributors for lower-volume markets.

• Listed public company: shares traded on Shenzhen Stock Exchange (300194.SZ), with a mix of state-invested/founding shareholders, management holdings and institutional investors forming the shareholder base.
• Group structure: parent company plus nine operating subsidiaries focused on manufacturing, R&D and regional marketing/distribution.

• Mission: develop and produce safe, high-quality pharmaceutical products to meet clinical and public health needs while expanding manufacturing and market reach.
• Strategy highlights:
  • Scale production capacity via subsidiary network and cGMP-compliant plants.
  • Broaden product mix across APIs and finished dosages to capture hospital and retail demand.
  • Leverage contract manufacturing to utilize excess capacity and diversify revenue.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): History

• Listed entity: Shenzhen Stock Exchange, stock code 300194.
• Registered capital: ≈ 281.99 million yuan.
• Shares outstanding (late 2025): ≈ 1.19 billion shares.
• Shareholder composition: mix of institutional investors, corporate stakeholders and individual shareholders.

• Financial structure emphasis: liquidity management, controlled leverage, capital allocation toward innovation.
• Operational focus enabled by ownership: scaling production, regulatory approvals, and commercial distribution.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): Ownership Structure

• Mission: Provide cost-effective, accessible essential medicines by prioritizing generics and efficient production.
• Values: Quality (cGMP adherence), integration (science-industry-commerce), affordability, and global service orientation.
• R&D structure: Dedicated research via subsidiaries including Ningbo Tianheng Pharmaceutical Co., Ltd. and Hubei Renmin Pharmaceutical Co., Ltd.

• How it makes money:
  • Manufacture and sale of generic drugs (volume-driven margins; price competitiveness).
  • Contract manufacturing and OEM supply leveraging cGMP plants.
  • R&D-driven product upgrades and approvals to broaden product listings and hospital procurement.
• Strategic advantages:
  • Chongqing location for logistics and access to domestic inland markets.
  • Integrated R&D subsidiaries enabling faster formulation development and regulatory filings.
  • Focus on essential medicines aligns with public procurement and reimbursement channels.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): Mission and Values

• Business model: Vertical integration across APIs → intermediates → FDFs.
• Scope: Research & development, pilot scale, commercial manufacturing, quality control and distribution.
• Quality standards: Facilities designed and operated in accordance with current Good Manufacturing Practice (cGMP) requirements.
• Workforce: Approximately 3,392 employees across operations, R&D, quality and commercial functions.
• Corporate HQ: No. 2 Huangyang Road, Yubei District, Chongqing, 401120, P.R. China.

• Subsidiaries: Nine specialized subsidiaries covering API production, intermediate synthesis, formulation and sales/marketing support.
• Manufacturing footprint: Production facilities equipped for multiple dosage forms and intermediate chemistries to support both domestic and export markets.
• Compliance & quality: cGMP-aligned production lines and quality management systems enabling regulatory filings and hospital/wholesale supply.

• API margins and scale: In-house API manufacturing reduces procurement costs and margin leakage, allowing higher gross margins on in-house formulations.
• Product mix: Revenues derive from bulk API sales, intermediate/custom synthesis projects and finished-dose product sales (branded generics, hospital supplies, export contracts).
• Integration benefits: Vertical integration shortens lead times, reduces dependency on third-party suppliers, and enables proprietary cost advantages on key intermediates.
• R&D-driven pipeline: Incremental revenue and margin expansion through new formulations, improved processes and registered generics for institutional buyers.

• Supply-chain control: Owning API and intermediate production reduces exposure to raw-material volatility and external capacity constraints.
• Quality & compliance: cGMP alignment supports tender-based hospital contracts and regulated export markets.
• Operational scale: Multiple subsidiaries focused on discrete steps in the value chain enable specialization and efficiency gains.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): How It Works

• Primary product categories: APIs, intermediates, finished dosage forms (tablets, injectables, etc.).
• Therapeutic coverage: anti-infective, anti-tumor, cardiovascular, digestive system drugs and others.
• Sales channels: direct sales to hospitals and distributors, exports to international markets, and partnerships for contract manufacturing.
• Operational base: strategically located production and logistics in Chongqing to serve inland China and support export logistics.

• API and intermediate manufacturing - long-term supply contracts with generic drug producers and export orders provide steady bulk revenue.
• Finished dosage forms - higher-margin sales through hospitals, regional distributors, and retail pharmacies for cardiovascular, anti-infective and digestive products.
• Contract manufacturing and toll production - leveraging production capacity and regulatory approvals to provide outsourced manufacturing services.
• Research-driven product upgrades - reformulations and process optimization that lower unit costs and improve profitability per product line.

• Diversified product portfolio across multiple therapeutic areas, reducing dependence on any single product.
• Vertical integration from intermediates to FDFs, capturing margin across the value chain.
• Scale and location advantages in Chongqing for logistics and lower manufacturing costs versus coastal peers.
• Improved operational efficiency reflected in 2024's net income rise despite lower revenue.

Fuan Pharmaceutical Co., Ltd. (300194.SZ): How It Makes Money

• Core revenue streams: sales of generic drugs and essential medicines, contract manufacturing and licensing of newly registered formulations.
• Cost drivers: production scale, raw-material prices, regulatory compliance and R&D investment for new registrations.
• Competitive dynamics: large state-owned conglomerates, multinational generics and numerous agile private producers vying on price and tender access.

• Market position: significant player in China's generic sector with emphasis on essential therapeutic areas and quality compliance to serve domestic demand.
• R&D stance: continued investment to secure product registrations and expand registered product list via subsidiaries.
• Outlook drivers: public tender outcomes, pricing pressure from competitors, cost control and successful commercialization of newly registered products.